Selux Diagnostics, which is leading a new era in personalized diagnostics to combat superbug infections and fight antibiotic resistance, has received a $2.8 million award from the U.S. National Institutes of Health (NIH) to help the company commercialize its NextGen ‘Phenotyping’ (NGP) platform for rapid antimicrobial susceptibility testing (AST). Having recently completed its first clinical trial and submitted the results to the U.S. Food and Drug Administration (FDA), Selux will use the NIH grant to fund three projects that advance the commercial readiness of the Selux NGP platform.
“Selux NGP is the only single-platform technology capable of delivering rapid AST results across a broad antibiotic menu for all sample types,” said Steve Lufkin, CEO of Selux. “By providing funding for Selux to scale manufacturing to lower costs and perform a multicentre study to compare NGP performance against legacy systems, this NIH funding will help Selux transform patient care for infectious diseases by positioning NGP as the dominant AST platform of the future.”
Selux’s breakthrough NGP technology works for all sample types and utilizes phenotypic AST – the only method that provides full actionable results indicating which therapies will effectively treat a patient’s infection.
With a comprehensive antibiotic menu that far surpasses the capabilities of current legacy AST systems, NGP can provide accurate, sameshift results for up to 50 antibiotics simultaneously. As a result, physicians can prescribe optimal treatment 3-5 days sooner, reducing hospital stays and de-escalating the cycle of antibiotic overuse and resistance.